CLL 1991: all centres/groups, trials/strata and treatments

Key: Green - ineligible for overview, nonstandard randomisation or otherwise excluded; Blue - data not (yet) received

14 Cancer and Leukemia Group B, U.S.A. {Canellos, McIntyre: SEP-1991}

1401 71A CLB-????: Stage III, IV; Entry 1971 to 1974; 103 patients were entered (not received)

1 Chlorambucil + Prednisone (monthly)
2 Chlorambucil + Prednisone (daily)
3 Prednisone

1402 76A CLB-????: Stage I, II; Entry 1976 to 1983; ? patients were entered (not received)

1 Control
2 Chlorambucil (intermittent)

1403 90C CLB-9011: Age > 18; B-cell; Entry 1990 ff; ? patients were entered (not received)

1 Fludarabine
2 Chlorambucil
3 Fludarabine + Chlorambucil

15 University of Cape Town, South Africa {:}

1501 80B SAFR-CT-LEU/LYM B: Entry 1980 to 1986; ? patients were entered (not received)

1 Chlorambucil + Prednisone
2 Total-body Irradiation

27 Medical Research Council, U.K. {:}

2701 78B1 MRC-CLL-1(a): Stage I static, II static; Entry 1978 to 1984; 78 patients were entered (not received)

1 Control
2 Chlorambucil

2702 78B2 MRC-CLL-1(b): Stage I progressive, II progressive, III, IV; Entry 1978 to 1981; ? patients were entered (not received)

1 Chlorambucil
2 Cyclophosphamide [125mg/m²/d for 5d] + Vincristine + Prednisolone

2703 78B3 MRC-CLL-1(c): Stage I progressive; Entry 1981 to 1984; ? patients were entered (not received)

1 Chlorambucil
2 Cyclophosphamide [250mg/m²/d for 5d] + Vincristine + Prednisolone

2704 78B4 MRC-CLL-1(d): Stage II progressive, III, IV; Entry 1978 to 1981; ? patients were entered (not received)

1 Chlorambucil
2 Cyclophosphamide + Vincristine + Prednisolone
3 Splenic Radiotherapy [100cGy/wk for 10wk]

2705 84B1 MRC-CLL-2(a): Stage A; Entry 1984 to 1990; 228 patients were entered (not received)

1 Control
2 Chlorambucil

2706 84B2 MRC-CLL-2(b): Stage B, C and Spleen < 5cm; Entry 1984 to 1990; ? patients were entered (not received)

1 Chlorambucil
2 Chlorambucil + Prednisone

2707 84B3 MRC-CLL-2(c): Stage B, C and Spleen > 5cm and radiotherapy available; Entry 1984 to 1990; ? patients were entered (not received)

1 Splenic Radiotherapy + Chlorambucil (if necessary)
2 Splenic Radiotherapy + (Chlorambucil + Prednisone) (if necessary)
3 Chlorambucil
4 Chlorambucil + Prednisone

2708 90B MRC-CLL-3: Stage A progressive, B, C; Entry 1990 ff; ? patients were entered (not received)

1 Chlorambucil
2 Chlorambucil + 4-Epi-Doxorubicin

2709 78B5 MRC-CLL-1(e): Stage II progressive, III, IV: Entry 1981 to 1984; ? patients were entered (not received)

1 Chlorambucil
2 Splenic Radiotherapy [100cGy/wk for 10wk]

28 National Cancer Institute, U.S.A. {:}

2801 Chemotherapy trial: Stage B, C; Entry ????; ? patients were entered (not received)

1 Chlorambucil
2 Fludarabine
3 Chlorambucil + Fludarabine

2802 79A NCI-79-C-80: Relapsed disease; Entry 1979 to 1982; ? patients were entered (not received)

1 Interferon
2 Poly-ICLC

35 PETHEMA, Spain {:}

3501 78A Chemotherapy trial: Stage C; Entry 1978 to 1983; 122 patients were entered (not received)

1 Chlorambucil + Prednisone
2 Cyclophosphamide + Vincristine + Prednisone

3502 88A1 Chemotherapy trial: Stage A; Entry 1988 to 1991; ? patients were entered (not received)

1 Control
2 Chlorambucil + Prednisone

3503 88A2 Chemotherapy trial: Stage B; Entry 1988 ff; ? patients were entered (not received)

1 Chlorambucil
2 Chlorambucil + Prednisone

3504 82C Chemotherapy trial: Stage B, C; Entry 1982 to 1988; 96 patients were entered (not received)

1 Chlorambucil + Prednisone
2 Cyclophosphamide + Melphalan + Prednisone

3505 88A3 Chemotherapy trial: Stage C; Entry 1988 ff; 57 patients were entered by FEB-1991 (not received)

1 Chlorambucil + Prednisone
2 Cyclophosphamide + Doxorubicin + Vincristine + Prednisone

37 Eastern Coöperative Oncology Group, U.S.A. {Carbone, Yeap: DEC-1991}

3701 76B EST-3476: Stage I-IV; Entry 1976 to 1980; 66 patients were entered (in process)

1 Chlorambucil + Prednisone
2 Total-body Irradiation / ³³P pilot study

3702 80C EST-2480: Stage II with progression, III, IV; Entry 1980 to 1983; 124 patients were entered (in process)

1 Chlorambucil + Prednisone
2 Cyclophosphamide + Vincristine + Prednisone

53 University of the Witwatersrand, Johannesburg, R.S.A. {Bezwoda: AUG-1991}

5301 91A NOPE Versus Chlorambucil: Entry 1991 ff; ? patients were entered (not received)

1 Mitozantrone + Vincristine + Prednisolone + Etoposide
2 Chlorambucil

80 Emory University School of Medicine, Atlanta, U.S.A. {:}

8001 88B EUCC-HIC-10588: Age > 18; Recurrent infection; Entry 1988 ff; ? patients were entered (not received)

1 Control
2 Human Immunoglobulin (iv)

84 Memorial Sloan Kettering Cancer Center, U.S.A. {Kempin: AUG-1992}

8401 83A MSKCC-8157: Age > 18; Stage B, C; Entry 1983 to 1989; 40 patients were entered (not received)

1 Cyclophosphamide + Prednisone
2 Cyclophosphamide + Prednisone + Total-body Irradiation

91 Roswell Park Memorial Institute, Buffalo, New York, U.S.A. {Han: MAR-1992}

9101 65A Roswell Park: Entry 1965 to 1970; 24 patients were entered (not received)

1 Chlorambucil [6mg/d] + Prednisone [30mg/d]
2 Chlorambucil [6mg/d]

93 Southeastern Cancer Study Group, U.S.A. {:}

9301 Chronic leukaemia trial: Entry ????; 50 C.L.L. patients were entered (not received)

1 Busulphan
2 Chlorambucil

9302 74A C.L.L. trial: Patients in C.R. or P.R; Entry 1974 to 1979; 97 patients were entered (not received)

1 Chlorambucil + Prednisone
2 Cytosine Arabinoside + Cyclophosphamide

9303 79B SEG-79-CLL-348: Entry 1979 to 1983; ? patients were entered (not received)

1 Chlorambucil + Prednisone
2 Chlorambucil + Prednisone + Total-body Irradiation

211 French Coöperative Group on C.L.L., France {Chastang: JUL-1991}

21101 80A1 FRE-CLL-80(a): Stage A; Entry 1980 to 1984; 612 patients were entered (not received)

1 Control
2 Chlorambucil (daily)

21102 80A2 FRE-CLL-80(b): Stage B; Entry 1980 to 1984; 291 patients were entered (not received)

1 Chlorambucil
2 Cyclophosphamide + Vincristine + Prednisone

21103 80A3 FRE-CLL-80(c): Stage C; Entry 1980 to 1984; 70 patients were entered (not received)

1 Cyclophosphamide + Adriamycin + Vincristine + Prednisone
2 Cyclophosphamide + Vincristine + Prednisone

21104 85A1 FRE-CLL-85(a): Stage A; Entry 1985 ff; 932 patients were entered (not received)

1 Control
2 Chlorambucil (intermittent)

21105 85A2 FRE-CLL-85(b): Stage B; Entry 1985 to 1989; 306 patients were entered (not received)

1 Cyclophosphamide + Adriamycin + Vincristine + Prednisone
2 Chlorambucil + Prednisone

21106 85A3 FRE-CLL-85(c): Stage C; Entry 1985 to 1989; 92 patients were entered (not received)

1 Cyclophosphamide + Adriamycin + Vincristine + Prednisone
2 Cyclophosphamide + Adriamycin + Vincristine + Prednisone + Methotrexate

21107 90A FRE-CLL-90: Stage B and C; Entry 1990 ff; ? patients were entered (not received)

1 Cyclophosphamide + Adriamycin + Vincristine + Prednisone
2 Chlorambucil + Adriamycin + Prednisolone
3 Fludarabine

212 Danish C.L.L. Study Group, Denmark {:}

21201 84A CLL-2: Stage B, C; Entry 1984 to 1989; 157 patients were entered (not received)

1 Prednisolone + Chlorambucil
2 Cyclophosphamide + Adriamycin + Vincristine + Prednisone

213 Lymphoma Group of Central Sweden, Sweden {:}

21301 82A Chemotherapy trial: Low grade NHL, including C.L.L. Stage III, IV; Entry 1982 to 1989; 109 C.L.L. patients were entered (not received)

1 Chlorambucil + Prednisone
2 Cyclophosphamide + Doxorubicin + Vincristine + Prednisone

21302 75A Chlorambucil/Prednimustine Trial: Entry 1975 to 1979; 123 patients were entered (not received)

1 Chlorambucil + Prednisolone
2 Prednimustine [20mg bd, po]
3 (Prednimustine [100mg bd, po] x 3d) every 2wk

214 University of Athens, Greece {:}

21401 __A1 Interferon Trial: Stage A: Entry ????; 34 patients were entered (not received)

1 Control
2 Alpha_2b-Interferon [1·5MU, daily]
3 Alpha_2b-Interferon [1·5MU, 3 times per wk]
4 Alpha_2b-Interferon [3·0MU, 3 times per wk]

21402 __A2 Induction trial: Any stage; Entry ????; ? patients were entered (not received)

1 Alpha-Interferon + Chlorambucil
2 Chlorambucil

21403 __A3 Maintenance trial: Patients in CR or PR; Entry ????; ? patients were entered (not received)

1 Alpha-Interferon
2 Control

215 IGCI, Croatia {:}

21501 82B1 IGCI-CLL-01(a): Early stable disease; low total tumour mass; Entry 1982 to 1986; 279 patients were entered (not received)

1 Control
2 Chlorambucil [high dose]
3 Chlorambucil + Prednisone

21502 82B2 IGCI-CLL-01(b): Advanced or progressive disease; high total tumour mass; Entry 1982 to 1986; 83 patients were entered (not received)

1 Chlorambucil [high dose]
2 Chlorambucil + Prednisone

21503 87A IGCI-CLL-02: Stage B, C; Entry 1987 ff; 105 patients were entered by NOV-1990 (not received)

1 Chlorambucil [high dose]
2 Cyclophosphamide + Doxorubicin + Vincristine + Prednisone

216 Berlin Free University, Germany {:}

21601 Chemotherapy trial: Low grade NHL, including C.L.L. Stage III, IV; Entry ????; ? patients were entered (not received)

1 Prednimustine
2 Chlorambucil + Prednisolone

217 Institute for Clinical and Experimental Cancer Research, Berne, Switzerland {:}

21701 Infection prophylaxis trial: Entry ????; ? patients were entered (not received)

1 Control
2 Immunoglobulin

218 John Radcliffe Hospital, Oxford, U.K. {:}

21801 __B1 Infection prophylaxis trial: Entry ????; ? patients were entered (not received)

1 Control
2 Immunoglobulin-G

21802 __B2 Infection prophylaxis trial: Low grade N.H.L. including C.L.L; Entry 1984 to 1985; 8 C.L.L. patients were entered (not received)

1 Control x 1yr then Immunoglobulin-G x 1yr
2 Immunoglobulin-G x 1yr

[End of document, updated to 26 September 2000]